{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:11:15Z","timestamp":1791591075245,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chongqing Medical Scientific Research project","award":["No. 2023ZDXM011"],"award-info":[{"award-number":["No. 2023ZDXM011"]}]},{"name":"CQMU Program for Youth Innovation in Future Medicine","award":["No. W0188"],"award-info":[{"award-number":["No. W0188"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12012-025-09990-6","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T01:21:33Z","timestamp":1744248093000},"page":"994-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predicting 30-Day Cardiotoxicity in Patients Receiving Immune Checkpoint Inhibitors: An Observational Study Utilizing XGBoost"],"prefix":"10.1007","volume":"25","author":[{"given":"Jialian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"10","key":"9990_CR1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante, N., Ram\u00edrez-Flores, Y. A., Castillo, E. C., Lozano, O., Garc\u00eda-Rivas, G., & Torre-Amione, G. (2021). Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis. European Journal of Heart Failure, 23(10), 1739\u20131747.","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"9990_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel, R. P., Parikh, R., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021). Cardiotoxicity of immune checkpoint inhibitors. Current Oncology Reports, 23(7), 79.","journal-title":"Current Oncology Reports"},{"issue":"17","key":"9990_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36(17), 1714\u20131768.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"9990_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.21037\/cdt-21-147","volume":"11","author":"A Portol\u00e9s Hern\u00e1ndez","year":"2021","unstructured":"Portol\u00e9s Hern\u00e1ndez, A., Blanco Clemente, M., Escribano Garc\u00eda, D., Velasco Calvo, R., N\u00fa\u00f1ez Garc\u00eda, B., Oteo Dom\u00ednguez, J. F., Salas Ant\u00f3n, C., M\u00e9ndez Garc\u00eda, M., Segovia Cubero, J., & Dom\u00ednguez, F. (2021). Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report. Cardiovascular Diagnosis and Therapy, 11(4), 1013\u20131019.","journal-title":"Cardiovascular Diagnosis and Therapy"},{"key":"9990_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15100","volume-title":"Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data","author":"P Jain","year":"2020","unstructured":"Jain, P., Bugarin, J. G., Guha, A., Jain, C., Shen, T., Stanevich, I., Margevicius, S. P., Fu, P., Liu, F., & Nikore, V. (2020). Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data. American Society of Clinical Oncology."},{"key":"9990_CR6","doi-asserted-by":"publisher","first-page":"922095","DOI":"10.3389\/fcvm.2022.922095","volume":"9","author":"X Peng","year":"2022","unstructured":"Peng, X., Zheng, Y., Zhu, Z., Liu, N., Zhou, S., & Long, J. (2022). Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury? Frontiers in Cardiovascular Medicine, 9, 922095.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"9990_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","volume":"6","author":"A Mecinaj","year":"2024","unstructured":"Mecinaj, A., Gulati, G., Ree, A. H., Gravdehaug, B., R\u00f8sj\u00f8, H., Steine, K., Wisl\u00f8ff, T., Geisler, J., Omland, T., & Heck, S. L. (2024). Impact of the ESC cardio-oncology guidelines biomarker criteria on incidence of cancer therapy-related cardiac dysfunction. JACC CardioOncology, 6(1), 83\u201395.","journal-title":"JACC CardioOncology"},{"issue":"Suppl_1","key":"9990_CR8","first-page":"A11777","volume":"144","author":"T Silva","year":"2021","unstructured":"Silva, T., Awadalla, M., Hassan, M., Zafar, A., Drobni, Z., Gongora, C., Mahmood, S. S., Zhang, L., Chen, C., & Ederhy, S. (2021). Global radial strain predicts cardiovascular events in patients with myocarditis related to the use of immune checkpoint inhibitors. Circulation, 144(Suppl_1), A11777\u2013A11777.","journal-title":"Circulation"},{"issue":"5","key":"9990_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","volume":"4","author":"Y Tamura","year":"2022","unstructured":"Tamura, Y., Tamura, Y., Takemura, R., Yamada, K., Taniguchi, H., Iwasawa, J., Yada, H., & Kawamura, A. (2022). Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy. JACC CardioOncology, 4(5), 673\u2013685.","journal-title":"JACC CardioOncology"},{"issue":"10","key":"9990_CR10","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.21037\/qims-22-41","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu, J., Cao, Y., Zhu, K., Yao, S., Yuan, M., Kong, X., Liu, X., Li, Y., Cui, Y., Han, X., et al. (2022). Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: A prospective observational study. Quantitative Imaging in Medicine and Surgery, 12(10), 4771\u20134785.","journal-title":"Quantitative Imaging in Medicine and Surgery"},{"issue":"8","key":"9990_CR11","doi-asserted-by":"publisher","first-page":"e38082","DOI":"10.2196\/38082","volume":"24","author":"J Li","year":"2022","unstructured":"Li, J., Liu, S., Hu, Y., Zhu, L., Mao, Y., & Liu, J. (2022). Predicting mortality in intensive care unit patients with heart failure using an interpretable machine learning model: Retrospective Cohort Study. Journal of Medical Internet Research, 24(8), e38082.","journal-title":"Journal of Medical Internet Research"},{"issue":"16","key":"9990_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.21037\/atm-22-3384","volume":"10","author":"Z Yan","year":"2022","unstructured":"Yan, Z., Wang, J., Dong, Q., Zhu, L., Lin, W., & Jiang, X. (2022). XGBoost algorithm and logistic regression to predict the postoperative 5-year outcome in patients with glioma. Annals of Translational Medicine, 10(16), 860.","journal-title":"Annals of Translational Medicine"},{"issue":"1","key":"9990_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12967-020-02620-5","volume":"18","author":"N Hou","year":"2020","unstructured":"Hou, N., Li, M., He, L., Xie, B., Wang, L., Zhang, R., Yu, Y., Sun, X., Pan, Z., & Wang, K. (2020). Predicting 30-days mortality for MIMIC-III patients with sepsis-3: A machine learning approach using XGboost. Journal of Translational Medicine, 18(1), 462.","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"9990_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020). NCCN guidelines insights: Management of immunotherapy-related toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230\u2013241.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"9990_CR15","first-page":"21","volume":"8","author":"MS Andres","year":"2022","unstructured":"Andres, M. S., Ramalingam, S., Rosen, S. D., Baksi, J., Khattar, R., Kirichenko, Y., Young, K., Yousaf, N., Okines, A., Huddart, R., et al. (2022). The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment\u202f: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology, 8(1), 21.","journal-title":"Cardiooncology"},{"issue":"41","key":"9990_CR16","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R., L\u00f3pez-Fern\u00e1ndez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229\u20134361.","journal-title":"European Heart Journal"},{"issue":"12","key":"9990_CR17","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J. P., Balko, J. M., Bonaca, M. P., et al. (2018). Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. The lancet Oncology, 19(12), 1579\u20131589.","journal-title":"The lancet Oncology"},{"issue":"16","key":"9990_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018). Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71(16), 1755\u20131764.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"9990_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.114.014508","volume":"131","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. (2015). Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. The TRIPOD Group. Circulation, 131(2), 211\u2013219.","journal-title":"Circulation"},{"issue":"10124","key":"9990_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet, 391(10124), 933.","journal-title":"The Lancet"},{"issue":"18","key":"9990_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine, 375(18), 1749\u20131755.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"9990_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/diagnostics13071243","volume":"13","author":"L Zotova","year":"2023","unstructured":"Zotova, L. (2023). Immune checkpoint inhibitors-related myocarditis: A review of reported clinical cases. Diagnostics (Basel), 13(7), 1243.","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"9990_CR23","doi-asserted-by":"publisher","first-page":"e004792","DOI":"10.1136\/jitc-2022-004792","volume":"11","author":"C Coustal","year":"2023","unstructured":"Coustal, C., Vanoverschelde, J., Quantin, X., Lesage, C., Michot, J. M., Lappara, A., Ederhy, S., Assenat, E., Faure, M., Issa, N., et al. (2023). Prognosis of immune checkpoint inhibitors-induced myocarditis: A case series. The Journal for ImmunoTherapy of Cancer, 11(5), e004792.","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"9990_CR24","doi-asserted-by":"publisher","first-page":"114912","DOI":"10.1016\/j.biopha.2023.114912","volume":"164","author":"A Mascolo","year":"2023","unstructured":"Mascolo, A., Sportiello, L., Rafaniello, C., Donniacuo, M., Ruggiero, D., Scisciola, L., Barbieri, M., Rossi, F., Paolisso, G., & Capuano, A. (2023). Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias? Biomedicine & Pharmacotherapy, 164, 114912.","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"17","key":"9990_CR25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.3390\/cancers15174293","volume":"15","author":"I Toribio-Garc\u00eda","year":"2023","unstructured":"Toribio-Garc\u00eda, I., Olivares-Hern\u00e1ndez, A., Miramontes-Gonz\u00e1lez, J. P., Dom\u00ednguez, L. P., Mart\u00edn Garc\u00eda, A., Eiros Bachiller, R., Figuero-P\u00e9rez, L., Garijo Mart\u00ednez, M., Rold\u00e1n Ruiz, J., Bellido Hern\u00e1ndez, L., et al. (2023). Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: Safety in real-world data. Cancers (Basel), 15(17), 4293.","journal-title":"Cancers (Basel)"},{"key":"9990_CR26","doi-asserted-by":"publisher","first-page":"986357","DOI":"10.3389\/fphar.2022.986357","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F., Wei, Q., & Wu, X. (2022). Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Frontiers in Pharmacology, 13, 986357.","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"9990_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s40001-023-01464-1","volume":"28","author":"FYN Lessomo","year":"2023","unstructured":"Lessomo, F. Y. N., Mandizadza, O. O., Mukuka, C., & Wang, Z. Q. (2023). A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. European Journal of Medical Research, 28(1), 495.","journal-title":"European Journal of Medical Research"},{"key":"9990_CR28","doi-asserted-by":"publisher","first-page":"104813","DOI":"10.1016\/j.compbiomed.2021.104813","volume":"137","author":"K Wang","year":"2021","unstructured":"Wang, K., Tian, J., Zheng, C., Yang, H., Ren, J., Liu, Y., Han, Q., & Zhang, Y. (2021). Interpretable prediction of 3-year all-cause mortality in patients with heart failure caused by coronary heart disease based on machine learning and SHAP. Computers in Biology and Medicine, 137, 104813.","journal-title":"Computers in Biology and Medicine"},{"issue":"6","key":"9990_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., Stein, F., Bretagne, M., Ederhy, S., Fenioux, C., et al. (2023). Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation, 148(6), 473\u2013486.","journal-title":"Circulation"},{"issue":"15","key":"9990_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/CIRCULATIONAHA.123.065988","volume":"148","author":"C deFilippi","year":"2023","unstructured":"deFilippi, C., & Barac, A. (2023). Cardiac troponins for diagnosis and prognostic assessment of immune checkpoint inhibitor myocarditis and myositis: The emerging importance of peripheral vision. Circulation, 148(15), 1135\u20131137.","journal-title":"Circulation"},{"key":"9990_CR31","doi-asserted-by":"publisher","first-page":"1350585","DOI":"10.3389\/fcvm.2024.1350585","volume":"11","author":"G Murtagh","year":"2024","unstructured":"Murtagh, G., deFilippi, C., Zhao, Q., & Barac, A. (2024). Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: Time for a risk-based approach. Frontiers in Cardiovascular Medicine, 11, 1350585.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"8","key":"9990_CR32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","volume":"23","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Dal Bello, M. G., Rijavec, E., Barletta, G., Rossi, G., & Biello, F. (2018). Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. The Oncologist, 23(8), 936\u2013942.","journal-title":"The Oncologist"},{"issue":"1","key":"9990_CR33","doi-asserted-by":"publisher","first-page":"24821","DOI":"10.1038\/s41598-024-76829-5","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen, Z., Lan, R., Ran, T., Tao, L., Zhu, Y., Li, Y., Zhang, C., Mao, M., Gao, D., & Zuo, Z. (2024). A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity. Science and Reports, 14(1), 24821.","journal-title":"Science and Reports"},{"issue":"4","key":"9990_CR34","doi-asserted-by":"publisher","first-page":"e13400","DOI":"10.1111\/eci.13400","volume":"51","author":"S Petricciuolo","year":"2021","unstructured":"Petricciuolo, S., Delle Donne, M. G., Aimo, A., Chella, A., & De Caterina, R. (2021). Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. European Journal of Clinical Investigation, 51(4), e13400.","journal-title":"European Journal of Clinical Investigation"},{"key":"9990_CR35","doi-asserted-by":"publisher","first-page":"914928","DOI":"10.3389\/fphar.2022.914928","volume":"13","author":"Y Lei","year":"2022","unstructured":"Lei, Y., Zheng, X., Huang, Q., Li, X., Qiu, M., & Liu, M. (2022). Intrinsic differences in immune checkpoint inhibitor-induced myocarditis: A retrospective analysis of real world data. Frontiers in Pharmacology, 13, 914928.","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"9990_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","volume":"115","author":"JR Power","year":"2022","unstructured":"Power, J. R., Alexandre, J., Choudhary, A., Ozbay, B., Hayek, S. S., Asnani, A., Tamura, Y., Aras, M., Cautela, J., Thuny, F., et al. (2022). Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Archives of Cardiovascular Diseases, 115(5), 315\u2013330.","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"3","key":"9990_CR37","doi-asserted-by":"publisher","first-page":"e002007","DOI":"10.1136\/jitc-2020-002007","volume":"9","author":"DA Zlotoff","year":"2021","unstructured":"Zlotoff, D. A., Hassan, M. Z. O., Zafar, A., Alvi, R. M., Awadalla, M., Mahmood, S. S., Zhang, L., Chen, C. L., Ederhy, S., Barac, A., et al. (2021). Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. The Journal for ImmunoTherapy of Cancer, 9(3), e002007.","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"9990_CR38","first-page":"34","volume":"9","author":"MP O'Shea","year":"2023","unstructured":"O\u2019Shea, M. P., Karikalan, S. A., Yusuf, A., Barry, T., Habib, E., O\u2019Shea, J., Killian, M., Baqal, E., Nayak, S., Masson, R., et al. (2023). Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis. Cardiooncology, 9(1), 34.","journal-title":"Cardiooncology"},{"issue":"19","key":"9990_CR39","doi-asserted-by":"publisher","first-page":"e19992","DOI":"10.1097\/MD.0000000000019992","volume":"99","author":"T Mizoguchi","year":"2020","unstructured":"Mizoguchi, T., Sugiura, T., Dohi, Y., Takase, H., Fujii, S., Seo, Y., & Ohte, N. (2020). Indices of left ventricular voltage on electrocardiogram are closely associated with serum cardiac troponin I levels in normotensive Japanese individuals. Medicine (Baltimore), 99(19), e19992.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"9990_CR40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/HJH.0b013e3280825638","volume":"25","author":"V Palmieri","year":"2007","unstructured":"Palmieri, V., Okin, P. M., de Simone, G., Bella, J. N., Wachtell, K., Gerdts, E., Boman, K., Nieminen, M. S., Dahl\u00f6f, B., & Devereux, R. B. (2007). Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of Hypertension, 25(5), 1079\u20131085.","journal-title":"Journal of Hypertension"},{"issue":"Suppl_3","key":"9990_CR41","doi-asserted-by":"publisher","first-page":"A17029","DOI":"10.1161\/circ.142.suppl_3.17029","volume":"142","author":"J Hu","year":"2020","unstructured":"Hu, J., Shnoda, M., Pappan, N., Kyvernitakis, A., & Poornima, I. G. (2020). Risk stratification and real world incidence of cardiac toxicity with immune checkpoint inhibitors. Circulation, 142(Suppl_3), A17029\u2013A17029.","journal-title":"Circulation"},{"issue":"3","key":"9990_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaccao.2020.07.005","volume":"2","author":"MYY Moey","year":"2020","unstructured":"Moey, M. Y. Y., Tomdio, A. N., McCallen, J. D., Vaughan, L. M., O\u2019Brien, K., Naqash, A. R., Cherry, C., Walker, P. R., & Carabello, B. A. (2020). Characterization of immune checkpoint inhibitor-related cardiotoxicity in lung cancer patients from a rural setting. JACC CardioOncology, 2(3), 491\u2013502.","journal-title":"JACC CardioOncology"},{"issue":"3","key":"9990_CR43","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ehf2.14340","volume":"10","author":"L Liang","year":"2023","unstructured":"Liang, L., Cui, C., Lv, D., Li, Y., Huang, L., Feng, J., An, T., Tian, P., Yang, K., Hu, L., et al. (2023). Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity. ESC Heart Failure, 10(3), 1907\u20131918.","journal-title":"ESC Heart Failure"},{"issue":"5","key":"9990_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/diseases12050088","volume":"12","author":"A Ali","year":"2024","unstructured":"Ali, A., Caldwell, R., Pina, G., Beinart, N., Jensen, G., Yusuf, S. W., Koutroumpakis, E., Hamzeh, I., Khalaf, S., Iliescu, C., et al. (2024). Elevated IL-6 and tumor necrosis factor-\u03b1 in immune checkpoint inhibitor myocarditis. Diseases, 12(5), 88.","journal-title":"Diseases"},{"issue":"6","key":"9990_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"TG Gergely","year":"2023","unstructured":"Gergely, T. G., Kucsera, D., T\u00f3th, V. E., Kov\u00e1cs, T., Sayour, N. V., Drobni, Z. D., Ruppert, M., Petrovich, B., \u00c1gg, B., On\u00f3di, Z., et al. (2023). Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. British Journal of Pharmacology, 180(6), 740\u2013761.","journal-title":"British Journal of Pharmacology"},{"issue":"22","key":"9990_CR46","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1161\/CIRCULATIONAHA.117.027272","volume":"135","author":"JA de Lemos","year":"2017","unstructured":"de Lemos, J. A., Ayers, C. R., Levine, B. D., deFilippi, C. R., Wang, T. J., Hundley, W. G., Berry, J. D., Seliger, S. L., McGuire, D. K., Ouyang, P., et al. (2017). Multimodality strategy for cardiovascular risk assessment: Performance in 2 population-based cohorts. Circulation, 135(22), 2119\u20132132.","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s12012-025-10002-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000}}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-09990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:06:49Z","timestamp":1749654409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-09990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9990"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-09990-6","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In Table 1 of this article, the data in the column headed hs-CRP (mg\/L), LDL (mmol\/L), IL-6 (pg\/ml) and IL-17A (pg\/ml) were mistakenly listed and it has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12012-025-10002-w","URL":"https:\/\/doi.org\/10.1007\/s12012-025-10002-w","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Approval No. 2024-107-01). The study adheres to the principles of medical ethics and the requirements of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}